BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alonso R, Pérez-García F, Ampuero D, Reigadas E, Bouza E. New direct-acting antivirals for patients with chronic HCV infection: can we monitor treatment using an HCV core antigen assay? Diagn Microbiol Infect Dis 2017;87:243-6. [PMID: 27916546 DOI: 10.1016/j.diagmicrobio.2016.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Pérez-garcía A, Aguinaga A, Navascués A, Castilla J, Ezpeleta C. Hepatitis C core antigen: Diagnosis and monitoring of patients infected with hepatitis C virus. International Journal of Infectious Diseases 2019;89:131-6. [DOI: 10.1016/j.ijid.2019.09.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Wang Y, Jie W, Ling J, Yuanshuai H. HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection. J Clin Lab Anal 2021;35:e23755. [PMID: 33788295 DOI: 10.1002/jcla.23755] [Reference Citation Analysis]
3 Abid A, Uddin M, Muhammad T, Awan S, Applegate T, Dore GJ, Cloherty G, Hamid S. Evaluation of Hepatitis C Virus Core Antigen Assay in a Resource-Limited Setting in Pakistan. Diagnostics (Basel) 2021;11:1354. [PMID: 34441289 DOI: 10.3390/diagnostics11081354] [Reference Citation Analysis]
4 Wasitthankasem R, Vichaiwattana P, Auphimai C, Siripon N, Klinfueng S, Tangkijvanich P, Vongpunsawad S, Poovorawan Y. HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs. PeerJ 2017;5:e4008. [PMID: 29134150 DOI: 10.7717/peerj.4008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
5 Mancebo Martínez A, Núñez Serrano P, Fernández de Cañete Camacho JC, Moreno Planas JM. Hepatitis C Virus Core Antigen as an Alternative to RNA in the Assessment of Response to Treatment with Direct-acting Oral Antivirals. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.118579] [Reference Citation Analysis]
6 Flores GL, Mota JC, da Silva Andrade LT, Lopes RS, Bastos FI, Villar LM, Komatsu H. Performance of HCV Antigen Testing for the Diagnosis and Monitoring of Antiviral Treatment: A Systematic Review and Meta-Analysis. BioMed Research International 2022;2022:1-17. [DOI: 10.1155/2022/7348755] [Reference Citation Analysis]
7 Khudur Al-Nassary MS, Mahdi BM. Study of Hepatitis C Virus Detection Assays. Ann Med Surg (Lond) 2018;36:47-50. [PMID: 30377525 DOI: 10.1016/j.amsu.2018.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Benito R, Arribas J, Algarate S, Cebollada R, Gude MJ. Hepatitis C virus core antigen for screening organ donors and recipients. Diagn Microbiol Infect Dis 2018;91:126-9. [PMID: 29477273 DOI: 10.1016/j.diagmicrobio.2018.01.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 McHugh MP, Wu AHB, Chevaliez S, Pawlotsky JM, Hallin M, Templeton KE. Multicenter Evaluation of the Cepheid Xpert Hepatitis C Virus Viral Load Assay. J Clin Microbiol 2017;55:1550-6. [PMID: 28275079 DOI: 10.1128/JCM.02460-16] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 6.6] [Reference Citation Analysis]
10 Aguilera A, Alados JC, Alonso R, Eiros JM, García F. Current position of viral load versus hepatitis C core antigen testing. Enferm Infecc Microbiol Clin (Engl Ed) 2020;38 Suppl 1:12-8. [PMID: 32111360 DOI: 10.1016/j.eimc.2020.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Saludes V, Antuori A, Lazarus JV, Folch C, González-Gómez S, González N, Ibáñez N, Colom J, Matas L, Casabona J, Martró E. Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain. Int J Drug Policy 2020;80:102734. [PMID: 32470849 DOI: 10.1016/j.drugpo.2020.102734] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]